title: Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
abstract: Cytokines and growth factors that influence both secretion of the extracellular matrix (ECM) proteins and migration of the cells decide about the final outcome of tissue remodelling. We have examined expression of the components of the plasminogen activation system in human astrocytoma U373-MG cells and found that interleukin 1beta (IL-1beta), tumour necrosis factor alpha TNF-alpha), interferon gamma (INF-gamma) and epidermal growth factor (EGF) specifically regulate the expression of tissue-type plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA), plasminogen activator inhibitor type 1 (PAI-1) and protease nexin-1 (PN-1). We conclude that EGF and IFN-gamma are new important regulators of the plasminogen activation system in astrocytoma cells and, therefore, may influence turnover of extracellular matrix and migration of cells within the brain.
authors.affiliation: Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Kasza
authors.forename: M
authors.initials: M
authors.lastname: Kowanetz
authors.forename: K
authors.initials: K
authors.lastname: Poślednik
authors.forename: B
authors.initials: B
authors.lastname: Witek
authors.forename: T
authors.initials: T
authors.lastname: Kordula
authors.forename: A
authors.initials: A
authors.lastname: Koj
mesh_terms: D016564:Amyloid beta-Protein Precursor; D001254:Astrocytoma; D002352:Carrier Proteins / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000378:metabolism* / Q000494:pharmacology / Q000502:physiology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism* / Q000494:pharmacology / Q000502:physiology; D007375:Interleukin-1 / Q000378:metabolism* / Q000494:pharmacology / Q000502:physiology; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics; D010960:Plasminogen Activators / Q000235:genetics*; D015849:Plasminogen Inactivators / Q000235:genetics; D058255:Protease Nexins; D012333:RNA, Messenger / Q000096:biosynthesis; D011956:Receptors, Cell Surface; D058258:Serpin E2; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000235:genetics; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism* / Q000494:pharmacology / Q000502:physiology; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics
chemical_list: D016564:Amyloid beta-Protein Precursor; D002352:Carrier Proteins; D007375:Interleukin-1; D017395:Plasminogen Activator Inhibitor 1; D015849:Plasminogen Inactivators; D058255:Protease Nexins; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; C545486:SERPINE2 protein, human; D058258:Serpin E2; D014409:Tumor Necrosis Factor-alpha; D004815:Epidermal Growth Factor; D007371:Interferon-gamma; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator